Karyopharm Therapeutics (KPTI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Karyopharm Therapeutics

NasdaqGS•Healthcare•Biotechnology

$1.62-0.07(-0.04%)After hours

Market Cap

$54,403.44

P/S

0.0x

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How this company scores

WeakMetricSide Score: 29/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (11/25); weakest: Balance Sheet & Red Flags (5/25).

Profitability7/25

Growth11/25

Balance Sheet & Red Flags5/25

Cash & Earnings Quality6/25

Strengths

Improving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.
Interest coverage below 1× (-1.6x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.0x5y range 0.0x – 7.5x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $54,403.44

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $146.62M
Q. Revenue: $33.43M
TTM EBITDA: $-82.00M
TTM Op. Income: $-82.35M
Q. Op. Income: $-22.53M
TTM Net Income: $-224.74M
Q. Net Income: $-67.02M
EPS: $-2.32
Shares Out.: $28,938

$146.62M in TTM revenue grew 6.8% YoY, reaching $33.43M last quarter. TTM EBITDA of $-82.00M and TTM operating income of $-82.35M show growth is flowing through to the bottom line. However, net income is negative at $224.74M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 7% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -67.4%
Op. Margin: -67.4%
Net Margin: -200.5%

Op. margin of -67.4% is down 3.1% YoY — costs are rising relative to revenue. Net margin at -200.5% Over the past year, operating margin is down 5% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.0x
P/B Ratio: N/A

P/S of 0.0x and P/B of 0.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $111.32M
Cash: $54.98M
Long-Term Debt: $85.05M
Book Value: $-330.17M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-24.93M
TTM Free Cash Flow: $-65.35M
FCF Margin: -44.6%
FCF / Net Income: 0.3

TTM FCF of $-65.35M on $-24.93M in operating cash flow. The FCF / Net Income ratio of 0.3x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 36% — a weakening trend.